Current Value
$55.231 Year Return
Current Value
$55.231 Year Return
Double maintains 3 strategies that include BMRN - BioMarin Pharmaceutical, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SHY | -0.08% | $23.85B | 0.15% |
BSV | 0.09% | $38.05B | 0.03% |
USO | 0.10% | $1.15B | 0.6% |
IBTP | -0.11% | $136.87M | 0.07% |
CARY | 0.20% | $347.36M | 0.8% |
TOTL | 0.22% | $3.83B | 0.55% |
USL | 0.23% | $44.65M | 0.85% |
BNO | -0.29% | $101.62M | 1% |
OILK | 0.31% | $78.31M | 0.69% |
SUB | 0.31% | $9.80B | 0.07% |
IBTO | -0.41% | $341.53M | 0.07% |
BAR | -0.44% | $1.14B | 0.1749% |
OUNZ | -0.45% | $1.74B | 0.25% |
SMB | 0.49% | $273.24M | 0.07% |
SPTL | 0.51% | $11.03B | 0.03% |
SMMU | 0.56% | $874.35M | 0.35% |
FLMI | -0.61% | $711.54M | 0.3% |
LDUR | -0.61% | $919.37M | 0.5% |
SHYD | 0.62% | $328.25M | 0.35% |
SCHQ | 0.67% | $787.20M | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 58.14% | $336.53M | 0.35% |
IBB | 56.87% | $5.44B | 0.45% |
PBE | 56.34% | $222.71M | 0.58% |
FBT | 55.92% | $997.89M | 0.54% |
VHT | 54.31% | $15.27B | 0.09% |
FHLC | 53.85% | $2.42B | 0.084% |
IYH | 53.52% | $2.76B | 0.39% |
XBI | 53.02% | $4.66B | 0.35% |
IXJ | 52.62% | $3.71B | 0.41% |
XLV | 52.56% | $33.98B | 0.09% |
RSPH | 52.50% | $720.89M | 0.4% |
MOAT | 50.39% | $13.76B | 0.47% |
GNOM | 49.95% | $43.17M | 0.5% |
FXH | 49.68% | $892.55M | 0.62% |
XPH | 49.67% | $148.95M | 0.35% |
PINK | 49.60% | $131.33M | 0.5% |
PPH | 49.49% | $563.37M | 0.36% |
IHE | 49.36% | $561.01M | 0.39% |
JEPI | 48.93% | $40.06B | 0.35% |
USMV | 48.60% | $23.51B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -42.99% | $101.78M | 0.59% |
VIXY | -40.86% | $185.08M | 0.85% |
FTSD | -19.13% | $228.56M | 0.25% |
IVOL | -18.52% | $349.05M | 1.02% |
FXY | -16.10% | $853.67M | 0.4% |
XONE | -15.37% | $640.90M | 0.03% |
ULST | -14.94% | $668.01M | 0.2% |
GBIL | -14.66% | $6.38B | 0.12% |
BTAL | -14.46% | $291.48M | 1.43% |
TPMN | -14.29% | $30.91M | 0.65% |
SPTS | -12.98% | $5.74B | 0.03% |
CLIP | -12.58% | $1.51B | 0.07% |
TBLL | -12.25% | $2.22B | 0.08% |
FXE | -11.04% | $563.87M | 0.4% |
SHV | -10.01% | $20.42B | 0.15% |
BWX | -9.96% | $1.47B | 0.35% |
VGSH | -9.23% | $22.55B | 0.03% |
STOT | -9.19% | $248.21M | 0.45% |
UTWO | -9.19% | $372.79M | 0.15% |
IBTG | -9.03% | $1.96B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLLS | 0.20% | $100.93M | -30.52% | 0.00% |
ASND | -0.25% | $10.31B | +38.57% | 0.00% |
CBOE | 0.27% | $23.83B | +34.36% | 1.10% |
EDSA | -0.35% | $14.29M | -52.23% | 0.00% |
GFI | -0.43% | $21.77B | +73.47% | 2.28% |
RDUS | 0.62% | $835.91M | +99.46% | 2.53% |
TH | -0.68% | $703.50M | -10.94% | 0.00% |
GALT | 0.75% | $208.23M | +41.20% | 0.00% |
BPT | -0.82% | $10.85M | -79.14% | 0.00% |
MVO | 0.82% | $68.54M | -35.50% | 20.88% |
VSA | -0.93% | $8.84M | -14.05% | 0.00% |
RLMD | -1.13% | $23.23M | -76.90% | 0.00% |
DRD | 1.18% | $1.22B | +67.74% | 1.99% |
VSTA | -1.22% | $350.48M | +43.28% | 0.00% |
ZCMD | 1.33% | $30.81M | +6.09% | 0.00% |
AIFU | -1.41% | $4.18B | +24.38% | 0.00% |
EVRI | 1.44% | $1.24B | +77.97% | 0.00% |
SAVA | 1.64% | $100.00M | -89.39% | 0.00% |
GORV | 1.65% | $25.88M | -92.85% | 0.00% |
SATS | -1.75% | $7.15B | +45.95% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -14.15% | $4.80K | -99.92% | 0.00% |
TDUP | -10.96% | $994.46M | +403.59% | 0.00% |
AQB | -10.54% | $3.06M | -52.64% | 0.00% |
HUSA | -7.92% | $27.45M | +41.13% | 0.00% |
K | -7.54% | $27.39B | +34.25% | 2.89% |
VHC | -7.03% | $33.48M | +63.90% | 0.00% |
STG | -5.94% | $28.54M | -22.35% | 0.00% |
UUU | -4.53% | $7.08M | +91.25% | 0.00% |
PSQH | -4.17% | $92.44M | -34.73% | 0.00% |
DFDV | -4.02% | $460.68M | +2,996.21% | 0.00% |
MKTX | -3.80% | $8.28B | +12.88% | 1.36% |
NUVL | -2.97% | $5.42B | -3.29% | 0.00% |
SYPR | -2.72% | $47.80M | +12.43% | 0.00% |
PHYS | -2.35% | - | - | 0.00% |
PRPO | -1.86% | $16.41M | +103.92% | 0.00% |
UFI | -1.85% | $90.33M | -10.55% | 0.00% |
RLX | -1.75% | $1.97B | +20.56% | 0.47% |
SATS | -1.75% | $7.15B | +45.95% | 0.00% |
AIFU | -1.41% | $4.18B | +24.38% | 0.00% |
VSTA | -1.22% | $350.48M | +43.28% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IQV | 47.16% | $26.75B | -27.36% | 0.00% |
TMO | 46.54% | $148.19B | -31.03% | 0.42% |
ITOS | 45.90% | $382.74M | -33.11% | 0.00% |
OBDC | 44.54% | $7.45B | -6.50% | 10.18% |
AAPL | 44.49% | $2.94T | -8.26% | 0.51% |
AMGN | 44.01% | $155.74B | -5.35% | 3.18% |
SLRC | 43.68% | - | - | 10.12% |
BRKR | 43.58% | $5.82B | -42.46% | 0.51% |
MTD | 43.46% | $23.81B | -22.66% | 0.00% |
ARCC | 43.09% | $15.07B | - | 8.91% |
BIIB | 42.81% | $18.54B | -43.42% | 0.00% |
RVTY | 42.27% | $11.13B | -12.00% | 0.29% |
NOVT | 42.25% | $4.39B | -26.19% | 0.00% |
IONS | 42.25% | $5.89B | -8.93% | 0.00% |
DD | 42.06% | $27.98B | -17.17% | 2.33% |
EFX | 42.03% | $31.47B | +4.79% | 0.65% |
TECH | 42.01% | $7.86B | -32.75% | 0.64% |
A | 41.96% | $32.82B | -14.37% | 0.83% |
KRYS | 41.76% | $3.82B | -23.65% | 0.00% |
AVB | 41.44% | $29.40B | +2.04% | 3.31% |
Yahoo
BioMarin Pharmaceutical (NASDAQ:BMRN) has had a rough three months with its share price down 22%. It seems that the...
Yahoo
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Yahoo
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 16 stocks Jim Cramer recently discussed. When a caller asked about the company during the lightning round, Cramer remarked: “You know what, BioMarin, I am getting tired of the orphan drug model. I just… [don’t] think that it’s working. I think it worked for some time. I […]
Yahoo
A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Yahoo
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Yahoo
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.